Literature DB >> 24961679

Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.

Jennifer A Flemming1, Parsia A Vagefi, Chris E Freise, Francis Y Yao, Norah A Terrault.   

Abstract

Older donor age is associated with lower graft and patient survival among all recipients of liver transplantation (LT). Among patients with hepatitis C virus (HCV), donor age is one of the strongest predictors of fibrosis severity and graft loss. We evaluated the implementation of a donor age restriction policy for LT patients with HCV at a single center and the effects that this policy had on wait-list (WL) and post-LT outcomes for HCV and non-HCV patients. This was a cohort study of 2388 WL patients and 1015 LT recipients between March 2002 and January 2013 and reflected 3 different eras of donor age policies. With the donor age restriction, the median donor age was reduced in LT recipients with HCV versus LT recipients without HCV (30 versus 48 years, P < 0.001) without differences in the WL time (10.6 versus 8.0 months, P = 0.23). According to a competing risks regression, those with HCV and those without HCV had lower subhazard ratios (SHRs) of dropout or death on the WL during the donor age restriction era versus the era without donor age restriction [SHR = 0.68 (P < 0.01) and SHR = 0.64 (P = 0.01), respectively]. No differences were seen in early post-LT survival for patients with or without HCV between eras (P = 0.7 and P = 0.88, respectively). In conclusion, we show that donor age restriction for HCV results in a lower donor age for HCV recipients without obvious adverse WL consequences. Although additional studies are needed, our results demonstrate the feasibility of donor age restriction for LT recipients with HCV, and such information may be relevant to programs with limited access to new antiviral therapies for which modifying the risk of severe disease remains of paramount importance.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24961679      PMCID: PMC4803440          DOI: 10.1002/lt.23937

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  19 in total

1.  OPTN/SRTR 2011 Annual Data Report: liver.

Authors:  W R Kim; P G Stock; J M Smith; J K Heimbach; M A Skeans; E B Edwards; A M Harper; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2013-01       Impact factor: 8.086

2.  Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation.

Authors:  Oscar Alonso; Carmelo Loinaz; Enrique Moreno; Carlos Jiménez; Manuel Abradelo; Ramón Gómez; Juan-Carlos Meneu; Carlos Lumbreras; Ignacio García
Journal:  Transpl Int       Date:  2005-08       Impact factor: 3.782

3.  Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men.

Authors:  Jennifer C Lai; Elizabeth C Verna; Robert S Brown; Jacqueline G O'Leary; James F Trotter; Lisa M Forman; Jeffrey D Duman; Richard G Foster; R Todd Stravitz; Norah A Terrault
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

4.  Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.

Authors:  Victor I Machicao; Hugo Bonatti; Murli Krishna; Bashar A Aqel; Frank J Lukens; Justin H Nguyen; Barry G Rosser; Raj Satyanarayana; Hani P Grewal; Winston R Hewitt; Denise M Harnois; Julia E Crook; Jeffery L Steers; Rolland C Dickson
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

5.  Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.

Authors:  Victoria Aguilera; Marina Berenguer; Angel Rubín; Fernando San-Juan; Jose-Miguel Rayón; Martín Prieto; José Mir
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799

6.  Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.

Authors:  Stephen C Rayhill; You Min Wu; Daniel A Katz; Michael D Voigt; Douglas R Labrecque; Patricia A Kirby; Frank A Mitros; Roberto S Kalil; Rachel A Miller; Alan H Stolpen; Warren N Schmidt
Journal:  Transplantation       Date:  2007-08-15       Impact factor: 4.939

7.  Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit.

Authors:  Michael R Lucey; Douglas E Schaubel; Mary K Guidinger; Santiago Tome; Robert M Merion
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

8.  Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.

Authors:  M Wali; R F Harrison; P J Gow; D Mutimer
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

9.  Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

Authors:  Marina Berenguer; Martín Prieto; Fernando San Juan; José M Rayón; Fernando Martinez; Domingo Carrasco; Angel Moya; Francisco Orbis; José Mir; Joaquín Berenguer
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

10.  Outcome after liver transplantation for cirrhosis due to alcohol and hepatitis C: comparison to alcoholic cirrhosis and hepatitis C cirrhosis.

Authors:  Ashwani K Singal; Bashar S Hmoud; Praveen Guturu; Yong-Fang Kuo
Journal:  J Clin Gastroenterol       Date:  2013-09       Impact factor: 3.062

View more
  2 in total

1.  The corrected donor age for hepatitis C virus-infected liver transplant recipients.

Authors:  Melisa Dirchwolf; Jennifer L Dodge; Jane Gralla; Kiran M Bambha; Trevor Nydam; Kenneth W Hung; Hugo R Rosen; Sandy Feng; Norah A Terrault; Scott W Biggins
Journal:  Liver Transpl       Date:  2015-08       Impact factor: 5.799

2.  Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Parsia A Vagefi; Jennifer L Dodge; Francis Y Yao; John P Roberts
Journal:  Liver Transpl       Date:  2015-02       Impact factor: 5.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.